Base de dados : MEDLINE
Pesquisa : D02.455.426.559.389.657.239.132 [Categoria DeCS]
Referências encontradas : 355 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 36 ir para página                         

  1 / 355 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28291237
[Au] Autor:Gimeno-García AZ; Hernandez G; Aldea A; Nicolás-Pérez D; Jiménez A; Carrillo M; Felipe V; Alarcón-Fernández O; Hernandez-Guerra M; Romero R; Alonso I; Gonzalez Y; Adrian Z; Moreno M; Ramos L; Quintero E
[Ad] Endereço:Departamento de Medicina Interna, Servicio de Gastroenterología, Hospital Universitario de Canarias, Instituto Universitario de Tecnologías Biomédicas (ITB) &Centro de Investigación Biomédica de Canarias (CIBICAN), Universidad de La Laguna, La Laguna, Spain.
[Ti] Título:Comparison of Two Intensive Bowel Cleansing Regimens in Patients With Previous Poor Bowel Preparation: A Randomized Controlled Study.
[So] Source:Am J Gastroenterol;112(6):951-958, 2017 Jun.
[Is] ISSN:1572-0241
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Inadequate bowel cleansing is a major burden for endoscopy units. The aim of this study was to compare two intensive bowel cleansing regimens in patients with previous colonoscopy with inadequate bowel preparation. METHODS: Patients with inadequate cleansing at index colonoscopy were randomized to 4-L split-dose polyethylene-glycol (PEG) regimen vs. 2-L split-dose PEG plus ascorbic acid (PEG+Asc) regimen. All individuals underwent a 3-day low-residue diet and received 10 mg of bisacodyl, the day before colonoscopy. Cleansing was considered to be adequate if the Boston Bowel Preparation Scale scored ≥2 at each colonic segment. A non-inferiority analysis was performed to demonstrate that colonic cleansing with 2-L PEG+Asc was not inferior to 4-l PEG, considering a non-inferiority margin of 10%. RESULTS: Adequate bowel cleansing was significantly higher in patients assigned to 4-L PEG regimen (n=127) vs. those randomized to 2-L PEG+Asc regimen (n=129) by intention-to-treat analysis (81.1 vs. 67.4%, odds ratio (OR) 2.07, 95% confidence interval (CI) (1.163-3.689)) and by per-protocol analysis (86.6 vs. 71.7%, OR: 2.55, 95% CI: (1.316-4.922)). The study was terminated for futility after the interim analysis, because the 95% CI of the difference of proportions was 3.13-24.27% in the intention-to-treat analysis and 3.33-26.47% in the per-protocol analysis, confirming the superiority of 4-L PEG preparation. CONCLUSIONS: After 3-day low-residue diet and oral bisacodyl before colonoscopy, colon cleansing with 4-L split-dose PEG was superior to 2-L split-dose PEG+Asc in patients with previous inadequate cleansing. (EUDRACT: 2013-002506-31, NCT02073552).
[Mh] Termos MeSH primário: Adenoma/diagnóstico
Catárticos/administração & dosagem
Pólipos do Colo/diagnóstico
Colonoscopia/métodos
Neoplasias Colorretais/diagnóstico
Polietilenoglicóis/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Ácido Ascórbico/administração & dosagem
Bisacodil/administração & dosagem
Catárticos/efeitos adversos
Ceco
Fibras na Dieta/administração & dosagem
Término Precoce de Ensaios Clínicos
Feminino
Seres Humanos
Análise de Intenção de Tratamento
Intubação Gastrointestinal
Masculino
Meia-Idade
Náusea/induzido quimicamente
Polietilenoglicóis/efeitos adversos
Vitaminas/administração & dosagem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Cathartics); 0 (Dietary Fiber); 0 (Vitamins); 10X0709Y6I (Bisacodyl); 30IQX730WE (Polyethylene Glycols); PQ6CK8PD0R (Ascorbic Acid)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170315
[St] Status:MEDLINE
[do] DOI:10.1038/ajg.2017.53


  2 / 355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28241037
[Au] Autor:Li Y; Jia X; Liu B; Qi Y; Zhang X; Ji R; Yu Y; Zuo X; Li Y
[Ad] Endereço:Department of Gastroenterology, Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan, China.
[Ti] Título:Randomized controlled trial: Standard versus supplemental bowel preparation in patients with Bristol stool form 1 and 2.
[So] Source:PLoS One;12(2):e0171563, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Bristol stool form 1 and 2 is an important predictor of inadequate bowel preparation. AIM: To evaluate the efficacy of supplemental preparation in bowel cleansing quality among patients with Bristol stool form 1 and 2, as well as the feasibility of tailored bowel preparation guided by Bristol stool form scale. METHODS: Patients with Bristol stool form 1 and 2 from 3 Chinese tertiary hospitals randomly received either 2 L PEG-ELP (group A) or 10 mg bisacodyl plus 2 L PEG-ELP (group B); patients with Bristol stool form 3 to 7 received 2 L PEG-ELP (group C) for bowel preparation. The primary endpoint is the rate of adequate bowel reparation for the whole colon. The adequate bowel preparation rate for separate colon segments, the polyp detection rate (PDR), tolerability, acceptability, sleeping quality and compliance were evaluated as secondary endpoints. RESULTS: 700 patients were randomized. In per-protocol analysis, patients in group B attained significantly higher successful preparation rate than group A (88.7% vs. 61.2%, p<0.001) and similar with group C (88.7% vs. 85.0%, p = 0.316). The PDR in group B was significantly higher than group A (43.2% vs. 25.7%, p<0.001). Acceptability was much higher in group B and C. CONCLUSIONS: 10 mg bisacodyl plus 2 L PEG-ELP can significantly improve both bowel preparation quality and PDR in patients with Bristol stool form 1 and 2. Bristol stool form scale may be an easy and efficient guide for tailored bowel preparation before colonoscopy.
[Mh] Termos MeSH primário: Catárticos/uso terapêutico
Colonoscopia/métodos
Intestinos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Adulto
Idoso
Bisacodil/administração & dosagem
China
Fezes
Feminino
Seres Humanos
Intestinos/fisiologia
Masculino
Meia-Idade
Cooperação do Paciente
Satisfação do Paciente
Pólipos/diagnóstico
Estudos Prospectivos
Centros de Atenção Terciária
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Cathartics); 10X0709Y6I (Bisacodyl)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170228
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0171563


  3 / 355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28109792
[Au] Autor:Dong J; Aulestia FJ; Assad Kahn S; Zeniou M; Dubois LG; El-Habr EA; Daubeuf F; Tounsi N; Cheshier SH; Frossard N; Junier MP; Chneiweiss H; Néant I; Moreau M; Leclerc C; Haiech J; Kilhoffer MC
[Ad] Endereço:Laboratoire d'Excellence Medalis, Université de Strasbourg, CNRS, LIT UMR 7200, F-67000 Strasbourg, France.
[Ti] Título:Bisacodyl and its cytotoxic activity on human glioblastoma stem-like cells. Implication of inositol 1,4,5-triphosphate receptor dependent calcium signaling.
[So] Source:Biochim Biophys Acta;1864(6):1018-1027, 2017 06.
[Is] ISSN:0006-3002
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Glioblastoma is the most common malignant brain tumor. The heterogeneity at the cellular level, metabolic specificities and plasticity of the cancer cells are a challenge for glioblastoma treatment. Identification of cancer cells endowed with stem properties and able to propagate the tumor in animal xenografts has opened a new paradigm in cancer therapy. Thus, to increase efficacy and avoid tumor recurrence, therapies need to target not only the differentiated cells of the tumor mass, but also the cancer stem-like cells. These therapies need to be effective on cells present in the hypoxic, slightly acidic microenvironment found within tumors. Such a microenvironment is known to favor more aggressive undifferentiated phenotypes and a slow-growing "quiescent state" that preserves the cells from chemotherapeutic agents, which mostly target proliferating cells. Based on these considerations, we performed a differential screening of the Prestwick Chemical Library of approved drugs on both proliferating and quiescent glioblastoma stem-like cells and identified bisacodyl as a cytotoxic agent with selectivity for quiescent glioblastoma stem-like cells. In the present study we further characterize bisacodyl activity and show its efficacy in vitro on clonal macro-tumorospheres, as well as in vivo in glioblastoma mouse models. Our work further suggests that bisacodyl acts through inhibition of Ca release from the InsP3 receptors.
[Mh] Termos MeSH primário: Bisacodil/farmacologia
Neoplasias Encefálicas/patologia
Sinalização do Cálcio
Glioblastoma/patologia
Receptores de Inositol 1,4,5-Trifosfato/metabolismo
Células-Tronco Neoplásicas/patologia
[Mh] Termos MeSH secundário: Neoplasias Encefálicas/metabolismo
Linhagem Celular Tumoral
Glioblastoma/metabolismo
Seres Humanos
Células-Tronco Neoplásicas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Inositol 1,4,5-Trisphosphate Receptors); 10X0709Y6I (Bisacodyl)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170123
[St] Status:MEDLINE


  4 / 355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27987136
[Au] Autor:Prasad VG; Abraham P
[Ad] Endereço:VGM Hospital, 2100, Trichy Road, Coimbatore, 641 005, India. drvgm@rediffmail.com.
[Ti] Título:Management of chronic constipation in patients with diabetes mellitus.
[So] Source:Indian J Gastroenterol;36(1):11-22, 2017 Jan.
[Is] ISSN:0975-0711
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:AIM: The aim of this review is to provide an overview of the clinical assessment and evidence-based treatment options for managing diabetes-associated chronic constipation. METHODS: A literature search of published medical reports in English language was performed using the OVID Portal, from PUBMED and the Cochrane Database of Systematic Reviews, from inception to October 2015. A total of 145 abstracts were identified; duplicate publications were removed and 95 relevant full-text articles were retrieved for potential inclusion. RESULTS: Chronic constipation is one of the most common gastrointestinal symptoms in patients with diabetes, and occurs more frequently than in healthy individuals. Treatment goals include improving symptoms and restoring bowel function by accelerating colonic transit and facilitating defecation. Based on guidelines and data from published literature, food and dietary change with exercise and lifestyle change should be the first step in management. For patients recalcitrant to these changes, laxatives should be the next step of treatment. Treatment should begin with bulking agents such as psyllium, bran or methylcellulose followed by osmotic laxatives if response is poor. Lactulose, polyethylene glycol and lactitol are the most frequently prescribed osmotic agents. Lactulose has a prebiotic effect and a carry-over effect (continued laxative effect for at least 6 to 7 days, post cessation of treatment). Stimulants such as bisacodyl, sodium picosulphate and senna are indicated if osmotic laxatives are not effective. Newer agents such as chloride-channel activators and 5-HT4 agonist can be considered for severe or resistant cases. CONCLUSION: The primary aim of intervention in diabetic patients with chronic constipation is to better manage the diabetes along with management of constipation. The physician should explain the rationale for prescribing laxatives and educate patients about the potential drawbacks of long-term use of laxatives. They should contact their physician if short-term use of prescribed laxative fails to provide relief.
[Mh] Termos MeSH primário: Constipação Intestinal/etiologia
Constipação Intestinal/terapia
Complicações do Diabetes/complicações
[Mh] Termos MeSH secundário: Bisacodil/administração & dosagem
Agonistas dos Canais de Cloreto/administração & dosagem
Doença Crônica
Citratos/administração & dosagem
Fibras na Dieta/administração & dosagem
Medicina Baseada em Evidências
Terapia por Exercício
Estilo de Vida Saudável
Seres Humanos
Laxantes/administração & dosagem
Metilcelulose/administração & dosagem
Compostos Organometálicos/administração & dosagem
Picolinas/administração & dosagem
Psyllium/administração & dosagem
Extrato de Sena/administração & dosagem
Agonistas de Receptores 5-HT4 de Serotonina/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Chloride Channel Agonists); 0 (Citrates); 0 (Dietary Fiber); 0 (Laxatives); 0 (Organometallic Compounds); 0 (Picolines); 0 (Serotonin 5-HT4 Receptor Agonists); 10X0709Y6I (Bisacodyl); 8013-11-4 (Senna Extract); 8063-16-9 (Psyllium); 9004-67-5 (Methylcellulose); LR57574HN8 (picosulfate sodium)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161218
[St] Status:MEDLINE
[do] DOI:10.1007/s12664-016-0724-2


  5 / 355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27287486
[Au] Autor:Nelson AD; Camilleri M; Chirapongsathorn S; Vijayvargiya P; Valentin N; Shin A; Erwin PJ; Wang Z; Murad MH
[Ad] Endereço:Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA.
[Ti] Título:Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis.
[So] Source:Gut;66(9):1611-1622, 2017 Sep.
[Is] ISSN:1468-3288
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare efficacy of pharmacotherapies for chronic idiopathic constipation (CIC) based on comparisons to placebo using Bayesian network meta-analysis. DATA SOURCES: We conducted searches (inception to May 2015) of MEDLINE, EMBASE, Scopus and Cochrane Central, as well as original data from authors or drug companies for the medications used for CIC. STUDY SELECTION: Phase IIB and phase III randomised, placebo-controlled trials (RCT) of ≥4 weeks' treatment for CIC in adults with Rome II or III criteria for functional constipation; trials included at least one of four end points. DATA EXTRACTION AND SYNTHESIS: Two investigators independently evaluated all full-text articles that met inclusion criteria and extracted data for primary and secondary end points, risk of bias and quality of evidence. OUTCOMES: Primary end points were ≥3 complete spontaneous bowel movements (CSBM)/week and increase over baseline by ≥1 CSBM/week. Secondary end points were change from baseline (Δ ) in the number of SBM/week and Δ CSBM/week. RESULTS: Twenty-one RCTs (9189 patients) met inclusion and end point criteria: 9 prucalopride, 3 lubiprostone, 3 linaclotide, 2 tegaserod, 1 each velusetrag, elobixibat, bisacodyl and sodium picosulphate (NaP). All prespecified end points were unavailable in four polyethylene glycol studies. Bisacodyl, NaP, prucalopride and velusetrag were superior to placebo for the ≥3 CSBM/week end point. No drug was superior at improving the primary end points on network meta-analysis. Bisacodyl appeared superior to the other drugs for the secondary end point, Δ in number of SBM/week. CONCLUSIONS: Current drugs for CIC show similar efficacy. Bisacodyl may be superior to prescription medications for Δ in the number of SBM/week in CIC.
[Mh] Termos MeSH primário: Compostos Azabicíclicos
Benzofuranos
Bisacodil
Citratos
Constipação Intestinal/tratamento farmacológico
Compostos Organometálicos
Picolinas
[Mh] Termos MeSH secundário: Compostos Azabicíclicos/administração & dosagem
Compostos Azabicíclicos/efeitos adversos
Benzofuranos/administração & dosagem
Benzofuranos/efeitos adversos
Bisacodil/administração & dosagem
Bisacodil/efeitos adversos
Doença Crônica
Citratos/administração & dosagem
Citratos/efeitos adversos
Constipação Intestinal/diagnóstico
Constipação Intestinal/fisiopatologia
Defecação/efeitos dos fármacos
Monitoramento de Medicamentos/métodos
Fármacos Gastrointestinais/administração & dosagem
Fármacos Gastrointestinais/efeitos adversos
Seres Humanos
Compostos Organometálicos/administração & dosagem
Compostos Organometálicos/efeitos adversos
Picolinas/administração & dosagem
Picolinas/efeitos adversos
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Azabicyclo Compounds); 0 (Benzofurans); 0 (Citrates); 0 (Gastrointestinal Agents); 0 (Organometallic Compounds); 0 (Picolines); 0 (TD-5108); 0A09IUW5TP (prucalopride); 10X0709Y6I (Bisacodyl); LR57574HN8 (picosulfate sodium)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160612
[St] Status:MEDLINE
[do] DOI:10.1136/gutjnl-2016-311835


  6 / 355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
PubMed Central Texto completo
Texto completo
[PMID]:27588943
[Au] Autor:Kwon JE; Lee JW; Im JP; Kim JW; Kim SH; Koh SJ; Kim BG; Lee KL; Kim SG; Kim JS; Jung HC
[Ad] Endereço:Department of Internal Medicine, The Armed Forces Capital Hospital, Bundang, Korea.
[Ti] Título:Comparable Efficacy of a 1-L PEG and Ascorbic Acid Solution Administered with Bisacodyl versus a 2-L PEG and Ascorbic Acid Solution for Colonoscopy Preparation: A Prospective, Randomized and Investigator-Blinded Trial.
[So] Source:PLoS One;11(9):e0162051, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Two liters of polyethylene glycol (PEG) solution administered with ascorbic acid (Asc) can provide efficacy similar to that of a 4-L PEG solution for colonoscopy preparation. In addition, oral bisacodyl (Bis) has been shown to reduce the volume of PEG needed for a bowel preparation with comparable efficacy. This study aimed to compare the efficacy, tolerability and safety of a 2-L PEG solution mixed with Asc versus the combination of Bis, Asc and a 1-L PEG solution. METHODS: This was a prospective, randomized, multi-centre, single-blind, non-inferiority trial. Participants who were scheduled for colonoscopy were included and randomized to receive either 2-L PEG and Asc (2L PEG/Asc group) or 1-L PEG, Asc and 20 mg Bis (1L PEG/Asc + Bis group). The quality of bowel preparation was assessed using the Boston Bowel Preparation Scale. Data regarding tolerance, compliance and adverse events were also gathered. RESULTS: A total of 187 participants were analyzed; 96 were allocated to the 2L PEG/Asc group and 91 to the 1L PEG/Asc + Bis group. Bowel preparation was adequate in 87.5% (84/96) of patients in the 2L PEG/Asc group and 94.5% of the 1L PEG/Asc + Bis group (86/91, p = 0.10). There was no significant difference between the two groups with respect to compliance, tolerability or safety. The patients allocated to the 1L PEG/Asc + Bis group expressed more willingness to repeat the procedure than patients in the 2L PEG/Asc group (p = 0.01). CONCLUSIONS: Bowel preparation with Bis and a 1-L PEG/Asc solution is as effective, well-tolerated, and safe as a 2-L PEG/Asc solution. TRIAL REGISTRATION: ClinicalTrials.gov NCT 01745835; Clinical Research Information Service (CRiS) KCT0000708.
[Mh] Termos MeSH primário: Ácido Ascórbico/administração & dosagem
Bisacodil/administração & dosagem
Catárticos/administração & dosagem
Colonoscopia/métodos
Satisfação do Paciente
Polietilenoglicóis/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Método Simples-Cego
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Cathartics); 10X0709Y6I (Bisacodyl); 30IQX730WE (Polyethylene Glycols); PQ6CK8PD0R (Ascorbic Acid)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170801
[Lr] Data última revisão:
170801
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160903
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0162051


  7 / 355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26912136
[Au] Autor:Fujita T; Karaki S; Tateoka T; Kuwahara A
[Ad] Endereço:Laboratory of Physiology, Department of Environmental and Life Sciences/Graduate School of Nutritional and Environmental Sciences, University of Shizuoka.
[Ti] Título:Desacetyl bisacodyl-induced epithelial Cl(-) secretion in rat colon and rectum.
[So] Source:Biomed Res;37(1):13-20, 2016.
[Is] ISSN:1880-313X
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to clarify the mode of desacetyl bisacodyl (DAB)-induced secretory action in intestinal tissues using an Ussing chamber assay. DAB is the active metabolite of the laxative bisacodyl. In mucosal-submucosal preparations, mucosal application of DAB induced a transient decrease followed by subsequent increases in short-circuit current and tissue conductance in a concentration-dependent manner. DAB-induced responses occurred from the middle colon to the rectal segment but not in the proximal colon. Moreover, these responses were not observed under chloride (Cl(-))-free conditions or in the presence of DAB on the serosal side of the mucosalsubmucosal specimens. Treatment with tetrodotoxin had no effect on the DAB-induced responses; however, mucosal treatment with a COX inhibitor piroxicam resulted in the elimination of responses. These results suggest that DAB may contribute to the laxative action by inducing Cl(-) secretion which is associated with the COX signaling pathway. This study also demonstrated that the DAB target molecule is present on the mucosal side from the middle colon to the rectal segment.
[Mh] Termos MeSH primário: Bisacodil/análogos & derivados
Cloretos/metabolismo
Colo/metabolismo
Mucosa Intestinal/efeitos dos fármacos
Mucosa Intestinal/metabolismo
Reto/metabolismo
[Mh] Termos MeSH secundário: Potenciais de Ação/efeitos dos fármacos
Animais
Bisacodil/farmacologia
Colo/fisiologia
Eletrólitos/metabolismo
Fenômenos Eletrofisiológicos/efeitos dos fármacos
Masculino
Ratos
Reto/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Chlorides); 0 (Electrolytes); 10X0709Y6I (Bisacodyl); R09078E41Y (dihydroxydiphenyl-pyridyl methane)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160226
[St] Status:MEDLINE
[do] DOI:10.2220/biomedres.37.13


  8 / 355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26820081
[Au] Autor:Fuccio L; Frazzoni L; Mussetto A
[Ti] Título:Reply to Azmi et al.
[So] Source:Endoscopy;48(2):198, 2016 Feb.
[Is] ISSN:1438-8812
[Cp] País de publicação:Germany
[La] Idioma:eng
[Mh] Termos MeSH primário: Bisacodil/administração & dosagem
Catárticos/administração & dosagem
Ácido Cítrico/administração & dosagem
Colectomia
Colo/efeitos dos fármacos
Colonoscopia/métodos
Polietilenoglicóis/administração & dosagem
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Cathartics); 10X0709Y6I (Bisacodyl); 2968PHW8QP (Citric Acid); 30IQX730WE (Polyethylene Glycols)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160129
[Lr] Data última revisão:
160129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160129
[St] Status:MEDLINE
[do] DOI:10.1055/s-0034-1393352


  9 / 355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26820080
[Au] Autor:Azmi AN; Chan WK; Mahadeva S; Goh KL
[Ti] Título:Split-dose low-volume bowel preparation, a feasible option for preparation for colonoscopy.
[So] Source:Endoscopy;48(2):197, 2016 Feb.
[Is] ISSN:1438-8812
[Cp] País de publicação:Germany
[La] Idioma:eng
[Mh] Termos MeSH primário: Bisacodil/administração & dosagem
Catárticos/administração & dosagem
Ácido Cítrico/administração & dosagem
Colectomia
Colo/efeitos dos fármacos
Colonoscopia/métodos
Polietilenoglicóis/administração & dosagem
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Cathartics); 10X0709Y6I (Bisacodyl); 2968PHW8QP (Citric Acid); 30IQX730WE (Polyethylene Glycols)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160129
[Lr] Data última revisão:
160129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160129
[St] Status:MEDLINE
[do] DOI:10.1055/s-0034-1393347


  10 / 355 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26760605
[Au] Autor:Zorzi M; Valiante F; Germanà B; Baldassarre G; Coria B; Rinaldi M; Heras Salvat H; Carta A; Bortoluzzi F; Cervellin E; Polo ML; Bulighin G; Azzurro M; Di Piramo D; Turrin A; Monica F; TriVeP Working Group
[Ad] Endereço:Veneto Cancer Registry, Regione Veneto, Padua, Italy.
[Ti] Título:Comparison between different colon cleansing products for screening colonoscopy. A noninferiority trial in population-based screening programs in Italy.
[So] Source:Endoscopy;48(3):223-31, 2016 Mar.
[Is] ISSN:1438-8812
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND STUDY AIMS: The high volume and poor palatability of 4 L of polyethylene glycol (PEG)-based bowel cleansing preparation required before a colonoscopy represent a major obstacle for patients. The aim of this study was to compare two low volume PEG-based preparations with standard 4 L PEG in individuals with a positive fecal immunochemical test (FIT) within organized screening programs in Italy. PATIENTS AND METHODS: A total of 3660 patients with a positive FIT result were randomized to receive, in a split-dose regimen, 4 L PEG or 2 L PEG plus ascorbate (PEG-A) or 2 L PEG with citrate and simethicone plus bisacodyl (PEG-CS). The noninferiority of the low volume preparations vs. 4 L PEG was tested through the difference in proportions of adequate cleansing. RESULTS: A total of 2802 patients were included in the study. Adequate bowel cleansing was achieved in 868 of 926 cases (93.7 %) in the 4 L PEG group, in 872 out of 911 cases in the PEG-A group (95.7 %, difference in proportions  + 1.9 %, 95 % confidence interval [CI]  - 0.1 to 3.9), and in 862 out of 921 cases in the PEG-CS group (93.6 %, difference in proportions  - 0.2 %, 95 %CI  - 2.4 to 2.0). Bowel cleansing was adequate in 95.5 % of cases when the preparation-to-colonoscopy interval was between 120 and 239 minutes, whereas it dropped to 83.3 % with longer intervals. Better cleansing was observed in patients with regular bowel movements (95.6 %) compared with those with diarrhea (92.4 %) or constipation (90.8 %). CONCLUSION: Low volume PEG-based preparations administered in a split-dose regimen guarantee noninferior bowel cleansing compared with 4 L PEG. Constipated patients require a personalized preparation. TRIAL REGISTRATION: EudraCT 2012 - 003958 - 82.
[Mh] Termos MeSH primário: Catárticos/administração & dosagem
Colonoscopia
[Mh] Termos MeSH secundário: Adulto
Idoso
Ácido Ascórbico/administração & dosagem
Bisacodil/administração & dosagem
Ácido Cítrico/administração & dosagem
Relação Dose-Resposta a Droga
Esquema de Medicação
Quimioterapia Combinada
Feminino
Seres Humanos
Itália
Masculino
Meia-Idade
Avaliação de Resultados (Cuidados de Saúde)
Polietilenoglicóis/administração & dosagem
Simeticone/administração & dosagem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Cathartics); 10X0709Y6I (Bisacodyl); 2968PHW8QP (Citric Acid); 30IQX730WE (Polyethylene Glycols); 8050-81-5 (Simethicone); PQ6CK8PD0R (Ascorbic Acid)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160114
[St] Status:MEDLINE
[do] DOI:10.1055/s-0035-1569574



página 1 de 36 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde